Navigation Links
BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
Date:4/10/2008

- Strategic Collaboration with the National Cancer Institute's NABTT

Consortium -

BRISBANE, Calif., April 10 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme (GBM), the most common glioma in adults. BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in BiPar's DNA repair portfolio, crosses the blood-brain barrier, a unique property that enables its targeted investigation in the brain tumor setting. This study is being conducted by investigators from the New Approaches to Brain Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research group. In addition to GBM, BiPar is currently enrolling BSI-201 in a randomized Phase 2 trial for triple-negative breast cancer and is initiating Phase 2 trials in uterine and BRCA-negative ovarian cancers.

"We believe a multi-drug strategy is the best approach to battling GBM. There is a significant need for new treatments that can offer GBM patients and their families additional hope," said Stuart A. Grossman, M.D., professor of oncology, medicine and neurological surgery at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital and the co-chairperson for this study.

"BSI-201 is a promising agent that has been well tolerated in combination with cytotoxic therapies in patients with solid tumors and potentially addresses a key pathway by which GBM cells resist the effects of existing medications. We are hopeful that BSI-201 will safely potentiate the power of current therapies for GBM and improve survival in this difficult-to-treat cancer," said Jaishri Blakeley, M.D., Assistant Professor of Neurology, Oncology and Neurosurgery at Johns Hopkins and the study chairperson for this study.

"The scientific observations that BSI-201 crosses the blood-brain barrier and has a mechanistic basis to synergize with the standard treatment of GBM makes this a promising study," said BiPar Executive Vice President Barry Sherman, M.D. "It is the promise of this approach that encouraged the leaders of NABTT to evaluate BSI-201 in patients with GBM."

GBM is an aggressive form of brain cancer that strikes 10,000 patients a year in the United States. Currently, patients are often treated with radiotherapy and chemotherapy where the median survival is under 15 months. The initial study phase will evaluate the safety and tolerability of BSI-201 in combination with temozolomide given at standard doses. The Phase 2 component will assess BSI-201 combined with temozolomide plus radiation therapy in newly diagnosed GBM patients, where the primary endpoint is overall survival.

Additional Data to be Presented at Upcoming AACR 2008 Meeting

BiPar will present preclinical data on BSI-201 at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on Monday, April 14, 2008. The abstract, "Activity of BSI-201, a potent poly (ADP-ribose) polymerase (PARP) inhibitor, alone and in combination with topotecan in human ovarian xenografts," will be presented at 8 a.m. in the "New Agents and Therapeutic Approaches" session.

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on novel mechanisms of action in oncology. Our existing platform is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. BSI-201 is the lead PARP inhibitor program in Phase 2 clinical trials in multiple solid tumor settings.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , Net Sales of $1.90 billion represent ... prior year period, and an increase of 1.2% on an ... for the first quarter were $0.52 reported, a decrease of ... increase of 29.9% over the prior year period , ... for 2016 Zimmer Biomet Holdings, Inc. (NYSE and ...
(Date:4/28/2016)... Calif. , April 28, 2016 /PRNewswire/ ... Validation Lifecycle Management Solutions (VLMS) today announced ... and services for sufferers of chronic kidney ... System to manage their corporate validation process. ... seeking a software solution to manage their ...
(Date:4/27/2016)... April 27, 2016 ... Forums in Zürich gab Strekin AG den ... STR001 zur Erhaltung des Resthörvermögens von Patienten, ... Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden ... STR001 wird während der Operation direkt ins ...
Breaking Medicine Technology:
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... ... Film Studios. With inMotion3D Abstract users can distort and manipulate three-dimensional shapes with ... position, rotation, columns, rows, ranks, point, lines, polygons, polygon texture animation, opacity texture ...
(Date:4/30/2016)... , ... April 30, 2016 ... ... CBC News on April 4th, 2016 questioned the use of the HyProCure ... EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, ...
(Date:4/29/2016)... ... 29, 2016 , ... In an article published April 16th on ... Botox and lip injections, which she underwent in order to feel more at home ... Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic ...
(Date:4/29/2016)... ... 29, 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown ... of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , ... 70% tax credit to individuals and corporations which donate directly to a “rural hospital” ...
(Date:4/29/2016)... Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... Monday, May 16, 2016, at its new location in the Exchange Furniture Mall at ... a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity ...
Breaking Medicine News(10 mins):